Search
  • mmahomed2
    • Sep 11, 2018
    • 1 min read

Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases

Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the development of a long-acting anti-inflammatory product that is designed for intra-articular administration. Specifically, we will evaluate the efficacy of our drug to prevent post-traumatic osteoarthritis following joint injuries

24 views0 comments

Recent Posts

See All

Series A financing

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

Phase I SBIR grant from the National Cancer Institute

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi

Valitor has recruited and hired Amy Twite, PhD

Valitor has recruited and hired Amy Twite, PhD to join our team as Director Chemistry. Amy graduated from UC Berkeley’s College of Chemistry with extensive experience in conjugation chemistry and cell